Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
LIAN LianBio
2.200-0.090-3.93%
Close
02/03 16:00 ET
2.100-0.100-4.55%
Post Mkt Price 02/03 17:34 ET
High
2.320
Open
2.200
Turnover
589.39K
Low
2.050
Pre Close
2.290
Volume
268.25K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
We Think LianBio (NASDAQ:LIAN) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l
Nanobiotix Randomizes 1st Patient in US in Phase 3 Head/neck Cancer Trial
LianBio Sponsored ADR (LIAN) Gets a Buy From Jefferies
Press Release: LianBio Announces President and Chief Strategy Officer Departure
LianBio Announces President and Chief Strategy Officer Departure SHANGHAI, China and PRINCETON, N.J., Dec. 13, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to br
LianBio Files $500 Million Mixed Shelf
04:03 AM EST, 11/11/2022 (MT Newswires) -- LianBio (LIAN) on Thursday filed a shelf registration statement for the potential sale of up to $500 million of its securities from time to time. The filing
LianBio Reports Q3 EPS (20c), Consensus (39c)
LianBio GAAP EPS of -$0.20
LianBio Q3 EPS $(0.20) Up From $(0.63) YoY
LianBio (NASDAQ:LIAN) reported quarterly losses of $(0.20) per share. This is a 68.25 percent increase over losses of $(0.63) per share from the same period last year.
Press Release: LianBio Reports Third Quarter 2022 -2-
global registrational trials and clinical development programs to obtain regulatory approval and maximize patient reach for its product candidates; the Company's ability to identify new product candid
LianBio to Participate in Upcoming Investor and Industry Events
SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major
Company Overview
More
LianBio operates as a biopharmaceutical company, which engages in the development and commercialization of medicines for patients with unmet medical needs. It develops a portfolio of clinically validated product candidates for cardiovascular, oncology, ophthalmology, inflammatory disease, and respiratory indications. The company was founded by Konstantin Poukalov on July 17, 2019 and is headquartered in Princeton, NJ.
CEO： Dr. Yizhe Wang, PhD
Market： NASDAQ
Listing Date： 11/01/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet